Tesamorelin vs HGH Fragment 176-191

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

HGH Fragment 176-191

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Full details →

Side-by-Side Comparison

AspectTesamorelinHGH Fragment 176-191
MechanismStimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.
Typical DosageFDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.
AdministrationSubcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.
Side EffectsCommon side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.
Best For

What They Have in Common

Both Tesamorelin and HGH Fragment 176-191 are commonly used for:

Key Differences

Ready to Learn More?